Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Acelity Introduces ALLODERM SELECT DUO™ Regenerative Tissue Matrix

Acelity L.P. Inc.
Posted on: 19 Oct 16

Acelity, a global advanced wound care and regenerative medicine company, announced today that ALLODERM SELECT DUOTM Regenerative Tissue Matrix is now available in the United States. ALLODERM™ Regenerative Tissue Matrix is the nation’s leading biological tissue matrix for soft tissue reinforcement in breast reconstruction procedures, with more than 1.4 million implants to date.The new offering is a matched tissue matrix pair intended for patients undergoing bilateral breast reconstruction that provides uniform tissue characteristics, including same donor, shape and thickness, allowing for a more consistent product experience for both plastic surgeons and patients.

“Reconstruction is an important part of the recovery process for many women who undergo mastectomy,” said Allen Gabriel, M.D., board-certified plastic surgeon at PeaceHealth Medical Group Plastic Surgery, Vancouver, Washington. “The ALLODERM SELECT DUO™ Tissue Matrix is an enhanced product offering for bilateral breast reconstruction, which are approximately 60 percent of all breast reconstructions performed. The matched pair from a single donor helps surgeons achieve their desired surgical outcomes and advances the art and practice of this critical component to women’s restoration and well being.”

ALLODERM SELECT DUO™ Regenerative Tissue Matrix delivers the regenerative qualities that surgeons have come to trust, while offering uniform tissue characteristics to better improve the bilateral breast reconstruction experience. Products in the ALLODERM™ Tissue Matrix portfolio are made from donated human dermis, processed to remove cells while preserving the essential biological components and structure of the dermal matrix to support tissue regeneration. Acelity uses proprietary processing that allows the matrices to support rapid revascularization, cell repopulation and white cell migration, offering surgeons a natural solution for soft tissue support where weakness exists.

This launch marks the third product advancement to the Acelity breast reconstruction portfolio in 2016. In May, Acelity launched the ALLODERM SELECT™ Regenerative Tissue Matrix brand that provides a consistent shape resulting from advanced cutting technology, a range of thicknesses to meet clinical needs (thin, medium, thick and x-thick), and an innovative packaging design that ensures consistently smooth and straight pieces. ALLODERM SELECT DUO™ is available in the updated thicknesses and improved packaging. In addition to ALLODERM SELECT™ and ALLODERM SELECT DUO™ Tissue Matrices, Acelity has initiated a limited launch of the ARTIA™ Reconstructive Tissue Matrix, a new porcine acellular dermal matrix, in the U.S. and full launch in Europe.

“For more than 20 years, surgeons have relied on ALLODERM™ Tissue Matrix as a leading product in breast reconstruction, and Acelity is committed to further advancing this technology so we can provide women facing mastectomy with enhanced and effective options,” said Joe Woody, president and chief executive officer of Acelity. “Our new breast reconstruction offerings are designed to improve the clinician and patient experience, and build upon the rich history and renowned ALLODERM™ Tissue Matrix brand that began with the product’s development at LifeCell. As part of the Acelity portfolio, we will continue to invest in innovation and expansion so that women who choose reconstruction, and the surgeons guiding their care, will have many more options available to them.”

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,800 people around the world.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005867/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.